A clinical policy bulletin from insurer Aetna (NYSE: AET ) yesterday has shares of Questcor (Nasdaq: QCOR ) under meaningful pressure today. In this video, Motley Fool health care analyst Brenton Flynn tells us why he thinks this might be a bit of an overreaction given that we heard the very same news from Aetna only months ago, and last night's announcement was only a reiteration of its policy.
Questcor is one of the most debated names in all of biotech. Its premium priced drug, Acthar, is growing at a torrid pace -- and minting money in the process. However, recent events have created significant doubts about Questcor's future. Will insurance companies continue to cover the drug? Will a government investigation lead to huge fines? We highlight these high-profile issues inside our brand new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.